Therapy News and Research

RSS

Health Research International publishes reports on opportunities presented by transcatheter and minimally invasive surgical valve technologies

Transcatheter heart valve technologies are positioned to become the next disruptive influence in cardiovascular medicine and drive a multi-billion dollar market. However, questions remain about the timing of adoption of these new technologies, the numbers and types of patients ultimately benefitting from them, the impact of reimbursement, and where transcatheter technologies pose the greatest threat to the current surgical caseload, especially in light of developments in minimally invasive heart valve surgery technologies.

19 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Researchers find connection between eye disease and arginase

Elevated levels of the enzyme arginase contribute to vascular eye damage and Medical College of Georgia researchers say therapies to normalize its levels could halt progression of potentially blinding diseases such as diabetic retinopathy.

19 Aug 2009

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.

19 Aug 2009

The Parkinson's Disease Foundation and the Davis Phinney Foundation jointly fund new study

The Davis Phinney Foundation, a non-profit organization dedicated to improving the lives of people with Parkinson's disease (PD) today, announced that it has awarded four Parkinson's disease research centers with support to conduct a landmark study on the long-term changes in quality of life and mobility that occur in people with PD. The results of this research will help to advance the understanding of how interventions, such as exercise, impact changes in quality of life and mobility over the course of the disease.

19 Aug 2009

HealthFitness chosen to lead MillerCoor's health management strategy

Health Fitness Corporation, a leading provider of integrated employee health and productivity management solutions, today announced that MillerCoors recently awarded HealthFitness an expanded role in leading its company-wide health management strategy.

19 Aug 2009

Light-activated delivery system enhances anti-tumour drug potency

The effects of tumour-targeting drugs in mice are significantly enhanced by PCI Biotech's light-activated delivery system, a new study shows. Researchers say this dual therapy approach could be employed to increase the effect and lower the side effects of anti-cancer drugs in humans.

19 Aug 2009

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

A study published in the Proceedings of the National Academy of Sciences (PNAS) shows that the virus blocks the actions of a specific ion channel in the cell membrane that would usually trigger apoptosis - the cell's self-destruct programme - and in doing so, has evolved another way of protecting itself from being eliminated from the body.

19 Aug 2009

Bioheart's executive management team strengthened by the inclusion of board members

Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.

19 Aug 2009

Siemens Healthcare's SOMATOM Emotion 16 ranked highest among 16-slice CT systems

According to a recent report from market research firm KLAS*, Siemens Healthcare's SOMATOM(R) Emotion CT scanner is ranked highest among 16-slice CT systems. Powerful and cost-effective, the SOMATOM Emotion 16 enables facilities to not only perform routine examinations, such as brain, chest, and abdomen examinations, but also undertake high-end, detailed examinations, such as high-resolution CT angiography, which greatly improve patient care, as well as diagnostic workflow.

19 Aug 2009

IVF treatment not to be combined with alternative therapies

Women who are desperately trying to get pregnant might want to avoid complementary and alternative medicine. The common belief is that it won't hurt to try alternative fertility treatments before reverting to in vitro fertilization (IVF). But a new study from Denmark finds that the success of IVF treatment is 30% lower among women who have used alternative medicine.

19 Aug 2009

Brooks Rehabilitation's new specialty clinic to provide advanced treatments for back and neck

Brooks Rehabilitation's newest specialty clinic, the Brooks Center for Back & Neck Health, offers patients advanced treatments for both acute and chronic conditions of the spine, including whiplash, lumbar stenosis, cervical or lumbar radiculopathy, cervical or lumbar instability, sciatica, TMJ, osteoarthritis, degenerative disc disease, and more. According to the National Institutes of Health, back pain is the second most common reason Americans go to the doctor (headaches are the first), and among the most common reasons for surgery. Research has demonstrated the effectiveness of physical therapy for affecting outcomes in patients with spinal conditions.

19 Aug 2009

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

The University of Southern California today announced that two faculty members from the USC Viterbi School of Engineering have been recognized by Technology Review magazine as some of the world's top innovators under the age of 35. Andrea Armani, Assistant Professor of Chemical Engineering and Materials Science, and Ellis Meng, Assistant Professor of Biomedical Engineering, will both appear on the prestigious 2009 TR35 list.

19 Aug 2009

Discovery of key factor that stimulates brain cancer cells to spread

Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme (GBM). In a move toward therapy, the researchers showed that a small designer protein can block this activity and reduce the spreading of GBM cells grown in the laboratory.

19 Aug 2009

Low-dose estrogen effective for metastatic breast cancer

When estrogen-lowering drugs no longer control metastatic breast cancer, the opposite strategy might work. Raising estrogen levels benefited 30 percent of women whose metastatic breast cancer no longer responded to standard anti-estrogen treatment, according to research conducted at Washington University School of Medicine in St. Louis and collaborating institutions.

19 Aug 2009

Medical fraud creates unknown amount of waste

Lawmakers seek a reduction in the amount of money lost each year to medical fraud. Meanwhile, two Miami doctors are convicted of Medicare fraud.

19 Aug 2009

FDA places Geron Corporation's IND for spinal cord injury on clinical hold

Geron Corporation (Nasdaq:GERN) today announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has been placed on clinical hold by the FDA pending the agency’s review of new nonclinical animal study data submitted by the company. A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial or to suspend an ongoing trial.

19 Aug 2009

Algos Therapeutics changes name to Algos Preclinical Services

Following a shift in its business model from developing proprietary pain therapy products to pure contract research, Algos Therapeutics has changed its name to Algos Preclinical Services. The company's new tagline, "Expertise in pain. Legendary service. Definitive results. For better quality of life." reinforces its repositioning as the go-to-CRO (Contract Research Organization) for drug discovery and product development.

19 Aug 2009

Abbott collaborates with Velcera to market pain management product for pets

Abbott (NYSE: ABT) announced today they have partnered with Velcera, Inc., a specialty pharmaceutical company focused on pet health, to market the first canine pain management product delivered in a transmucosal mist form. Currently in clinical trials, the product combines the proven pain medication meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with Velcera's patented Promist(TM) technology, and has been globally licensed for pain management in dogs

19 Aug 2009

Advantage Capital Partners' funding enables Current Solutions to acquire Koalaty Products

Advantage Capital Partners, a leading venture capital and small business finance firm, has provided $3.15 million in financing to Current Solutions, LLC, a wholesale distributor of electrotherapy devices and accessories to medical supply organizations throughout the United States and Canada. The funding, made in connection with the Texas Certified Capital Company (CAPCO) program, enabled Current Solutions to acquire Koalaty Products, Inc. and will support the company’s move from Tampa, Fla. to Austin, Texas.

19 Aug 2009

Therapy News and Research

Health Research International publishes reports on opportunities presented by transcatheter and minimally invasive surgical valve technologies

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Researchers find connection between eye disease and arginase

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

The Parkinson's Disease Foundation and the Davis Phinney Foundation jointly fund new study

HealthFitness chosen to lead MillerCoor's health management strategy

Light-activated delivery system enhances anti-tumour drug potency

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

Bioheart's executive management team strengthened by the inclusion of board members

Siemens Healthcare's SOMATOM Emotion 16 ranked highest among 16-slice CT systems

IVF treatment not to be combined with alternative therapies

Brooks Rehabilitation's new specialty clinic to provide advanced treatments for back and neck

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

Discovery of key factor that stimulates brain cancer cells to spread

Low-dose estrogen effective for metastatic breast cancer

Medical fraud creates unknown amount of waste

FDA places Geron Corporation's IND for spinal cord injury on clinical hold

Algos Therapeutics changes name to Algos Preclinical Services

Abbott collaborates with Velcera to market pain management product for pets

Advantage Capital Partners' funding enables Current Solutions to acquire Koalaty Products

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News